Janssen Research and Development

Janssen Research and Development Submits New Diabetes Treatment

The new drug application submitted to the FDA is a fixed-dose combination therapy for patients with Type 2 diabetes.

Janssen Research & Development, LLC  today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes.

No votes yet
Syndicate content